Necmettin Erbakan University
erbakan.edu.trTotal trials
181
Active
44
Phase 3
0
Total enrollment
17,471
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 1 of 1 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Adenosine deaminase acting on RNA1 | — | — | — | — | — | 1 |
Next readouts
- 2026-07-01
Top conditions
- Pain9
- Periodontal Diseases9
- Anxiety5
- Periodontitis5
- Gingival Recession4
- Breast Cancer4
- Satisfaction3
- Nurse's Role3
Frequently asked questions about Necmettin Erbakan University
- How many clinical trials does Necmettin Erbakan University have on ClinicalTrials.gov?
- Necmettin Erbakan University is listed as the lead sponsor on 181 clinical trials in ClinicalTrials.gov, 44 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Necmettin Erbakan University's trials are in Phase 3?
- 0 of Necmettin Erbakan University's trials are in Phase 3, spread across 1 active drug program.
- What therapeutic areas does Necmettin Erbakan University focus on?
- Necmettin Erbakan University's most-studied conditions on ClinicalTrials.gov are Pain, Periodontal Diseases, Anxiety, Periodontitis, Gingival Recession.
- When are Necmettin Erbakan University's next clinical trial readouts?
- Necmettin Erbakan University has 1 upcoming primary-completion readout tracked here; the soonest is “ADAR1 Expression Level in Rectal Cancer”, expected around 2026-07-01.